Targeted Oncology5h
Radiotherapy and Abiraterone Improve Outcomes in Low-Volume mCSPC
The PEACE-1 trial (NCT01957436) revealed that adding radiotherapy to standard of care (SOC) and abiraterone significantly ...
Healio5h
FDA approves therapies for colorectal cancer, mantle cell lymphoma
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...
OS Therapies price target raised to $15 from $8 at Maxim
Maxim analyst Jason McCarthy raised the firm’s price target on OS Therapies (OSTX) to $15 from $8 and keeps a Buy rating on the shares. The firm cites the company’s positive Phase 2b top-line data for ...
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral ...
Autolus Therapeutics presents clinical data updates at Tandem Meetings
Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings ...
OS Therapies’ (OSTX) Buy Rating Reiterated at D. Boral Capital
OS Therapies (NYSE:OSTX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a ...